MCM4 and malignant peripheral nerve sheath tumor: To explore whether our findings derived from LPS could be broadened to a wider pan-sarcoma population, 263 STS specimens from TCGA-SARC (Cerami et al., 2012), including 104 leiomyosarcoma, 58 DDLS, 49 undifferentiated pleomorphic sarcoma, 25 myxofibrosarcoma, 10 synovial sarcoma, 9 malignant peripheral nerve sheath tumor, 4 sarcoma NOS (not otherwise specified), 2 PLS, and 2 desmoid fibromatosis, were assessed for MCM4 expression (Figure 4B).